Versartis, Inc. Form 8-K March 06, 2015

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

# **CURRENT REPORT**

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 6, 2015

# Versartis, Inc.

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction


001-36361 (Commission 26-4106690 (IRS Employer

of incorporation) File Number) Identification No.)

# Edgar Filing: Versartis, Inc. - Form 8-K

4200 Bohannon Drive, Suite 250

Menlo Park, California 94025 (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (650) 963-8580



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: Versartis, Inc. - Form 8-K

#### Item 7.01 Regulation FD Disclosure.

Spokespersons of Versartis, Inc. (the Company) plan to present the information in the presentation poster attached hereto as Exhibit 99.1 at The Endocrine Society s 97th Annual Meeting and Expo (ENDO 2015) in San Diego, CA on March 6, 2015.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the poster is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the Securities and Exchange Commission (the SEC) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

#### Item 8.01 Other Events.

On March 6, 2015, the Company announced it was selected to present data from its ongoing Extension Study of pre-pubertal children with moderate growth hormone deficiency (GHD) in a poster presentation at The Endocrine Society s 97th Annual Meeting & Expo (ENDO 2015) in San Diego, CA. A copy of the press release regarding this announcement, titled Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine Society s Annual Meeting is attached as Exhibit 99.2 hereto and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No. Description

99.1 Company poster presentation dated March 2015

99.2 Press release dated March 6, 2015, titled Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine

Society s Annual Meeting

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 6, 2015

Versartis, Inc.

By: /s/ Joshua T. Brumm Joshua T. Brumm Chief Financial Officer

### INDEX TO EXHIBITS

$\mathbf{r}_{2}$	1	.:1	٠:٠	
He	٧ŀ	11	าป	

No. Description

99.1 Company poster presentation dated March 2015

99.2 Press release dated March 6, 2015, titled Versartis Presents 12-Month Data for VRS-317 at Late-Breaker Session at Endocrine

Society s Annual Meeting